(PRESS RELEASE) PARIS, 20-Jul-2021 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused on human health, has announced fexinidazole approval by the US Food and Drug Administration (FDA) as the first all-oral treatment for both stages of the … Read the full press release
Posted in France, Healthcare, News, Pharma & Biotech
Tagged Central African Republic, Democratic Republic of Congo, DNDi, Dr Bernard Pécoul, Drugs for Neglected Diseases initiative, FDA, fexinidazole, HAT, Human African trypanosomiasis, Luc Kuykens, National Sleeping Sickness Programs, neuropsychiatric symptoms, parasitic disease, Sanofi, sleeping sickness, Trypanosoma brucei gambiense, tse-tse fly, US Food and Drug Administration, WHO, World Health Organization
Accelerating projects on access to medicines, support for vulnerable communities, environmental conservation, and diversity and inclusion Creation of Sanofi Global Health, global nonprofit unit to provide 40 of the world’s poorest countries access to 30 essential medicines (PRESS RELEASE) PARIS, 7-Apr-2021 — … Read the full press release
Posted in France, Healthcare, News, Non Profit, Pharma & Biotech, Society
Tagged access to medicines, Cancer, cardiovascular disease, chronic diseases, climate change, Corporate Social Responsibility, CSR strategy, Diabetes, diversity, environmental protection program, Fabry, Gaucher, healthcare professionals, Inclusion, malaria, nonprofit unit, open letter, Paul Hudson, Pharmaceutical, Planet Mobilization, polio, Pompe diseases, preservation of the environment, rare diseases, Sanofi, Sanofi Global Health, sleeping sickness, support for vulnerable communities, tuberculosis, vaccines, WHO, World Health Organization, Zero plastic packaging
LONDON, 09-Aug-2016 — /EuropaWire/ — Scientists have identified a compound that can kill the parasites responsible for three neglected diseases: Chagas disease, leishmaniasis and sleeping sickness. These diseases affect millions of people in Latin America, Asia and Africa, but there are … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
